{
    "clinical_study": {
        "@rank": "48547", 
        "arm_group": {
            "arm_group_label": "Decitabine and cytarabine", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the safety and efficacy of decitabine in sequential\n      administration with cytarabine in children with relapsed or refractory acute myeloid\n      leukemia (AML)."
        }, 
        "brief_title": "A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia", 
        "completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myeloid Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label (identity of assigned study drug will be known) study to evaluate\n      safety, efficacy, and pharmacokinetics (study of what the body does to a drug) of decitabine\n      in sequential administration with cytarabine in children with relapsed or refractory AML.\n      The study will determine the maximum tolerated dose of cytarabine that can be given\n      following decitabine (Phase 1) and the response rate to this combination (Phase 2).\n      Participants may enter a continuation phase of single agent-decitabine infusions for as long\n      as such treatment would be considered beneficial. Serial pharmacokinetic samples will be\n      collected and safety and efficacy will be monitored throughout the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological diagnosis of acute myeloid leukemia (AML) according to the World Health\n             Organization (WHO) classification\n\n          -  Diagnosis of AML which has relapsed or is refractory to standard of care and no\n             curative therapy exists\n\n          -  Karnofsky or Lansky score of at least 50\n\n          -  Must be recovered from acute toxicity of any prior treatment\n\n          -  Must have adequate organ function according to protocol-defined criteria\n\n          -  Agrees to protocol-defined use of effective contraception\n\n          -  Female participants of childbearing potential must have a negative serum or urine\n             pregnancy test at Day 1 of Cycle 1\n\n          -  Female participants must agree not to donate eggs (ova, oocytes) for the purposes of\n             assisted reproduction\n\n          -  Male participants must not donate sperm during the study and for 3 months after\n             receiving the last dose of study drug\n\n        Exclusion Criteria:\n\n          -  Prior treatment with decitabine or azacitidine\n\n          -  Acute promyelocytic leukemia (M3 subtype in the French-American-British [FAB]\n             classification system)\n\n          -  Symptomatic central nervous system involvement of acute myeloid leukemia (AML)\n\n          -  AML associated with congenital syndromes such as Down syndrome, Fanconi anemia, Bloom\n             syndrome, Kostmann syndrome or Diamond-Blackfan anemia, or bone marrow failure\n             associated with inherited syndromes\n\n          -  White blood cell count greater than 40,000 cells/mL\n\n          -  Known allergies, hypersensitivity, or intolerance to decitabine or cytarabine or\n             their excipients\n\n          -  Contraindications to the use of cytarabine per local prescribing information or prior\n             adverse reactions to cytarabine which would prevent further use\n\n          -  Currently enrolled in an interventional investigational study\n\n          -  Female who is pregnant, or breast-feeding, or planning to become pregnant while\n             enrolled in this study or within 3 months after the last dose of study drug (however,\n             the period after which it becomes safe to become pregnant after the last dose of\n             treatment is not known)\n\n          -  Male who plans to father a child while enrolled in this study or within 3 months\n             after the last dose of study drug\n\n          -  Any condition for which, in the opinion of the investigator, participation would not\n             be in the best interest of the patient or that could prevent, limit, or confound the\n             protocol-specified assessments\n\n          -  Any social or medical condition that in the investigator's opinion renders the\n             participant unfit for study participation\n\n          -  History of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV)\n             positive, or other clinically active liver disease\n\n          -  History of human immunodeficiency virus (HIV) antibody positive"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01853228", 
            "org_study_id": "CR102071", 
            "secondary_id": [
                "DACOGENAML2004", 
                "2013-000390-70"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Decitabine and cytarabine", 
                "description": "20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)", 
                "intervention_name": "Phase1 and Phase 2: decitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Decitabine and cytarabine", 
                "description": "1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose", 
                "intervention_name": "Phase 1: cytarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Decitabine and cytarabine", 
                "description": "Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)", 
                "intervention_name": "Phase 2: cytarabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Decitabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Acute myeloid leukemia", 
            "Relapsed or refractory acute myeloid leukemia", 
            "Children", 
            "Decitabine", 
            "DACOGEN", 
            "Cytarabine"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "link": {
            "description": "To learn how to participate in this trial please click here.", 
            "url": "http://pam.sylogent.com/cr/CR102071"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Copenhagen \u00d8", 
                        "country": "Denmark"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse Cedex 9", 
                        "country": "France"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bristol", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sutton", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Denmark", 
                "France", 
                "Germany", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia", 
        "overall_contact": {
            "email": "JNJ.CT@sylogent.com", 
            "last_name": "Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:"
        }, 
        "overall_official": {
            "affiliation": "Janssen Research & Development, LLC", 
            "last_name": "Janssen Research & Development, LLC Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Phase 1 maximum tolerable dose of cytarabine", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 28"
            }, 
            {
                "measure": "Phase 1 maximum plasma concentration of decitabine", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 5"
            }, 
            {
                "measure": "Phase 1 area under the concentration time curve of decitabine", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 5"
            }, 
            {
                "measure": "Phase 1 time to maximum plasma concentration of decitabine", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 5"
            }, 
            {
                "measure": "Phase 1 clearance of decitabine", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 Day 5"
            }, 
            {
                "measure": "Phase 2 response rate", 
                "safety_issue": "No", 
                "time_frame": "Day 28 of last Phase 2 study drug treatment cycle"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01853228"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "From time of response to relapse, study completion/withdrawal, or death, whichever comes first, for up to 3 years after last participant enrollment"
            }, 
            {
                "measure": "Overall response", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 cycles of treatment"
            }, 
            {
                "measure": "Event-free survival", 
                "safety_issue": "No", 
                "time_frame": "From enrollment to progression/relapse, death, or withdrawal, whichever comes first, for up to 3 years after last participant enrollment"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From enrollment to death or withdrawal, whichever comes first, for up to 3 years after last participant enrollment"
            }, 
            {
                "measure": "Number of participants affected by an adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after the last dose of study medication"
            }
        ], 
        "source": "Janssen Research & Development, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}